MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
PerkinElmer profts inch down despite 14 percent sales increase
PerkinElmer Inc. (NYSE:PKI) posted profits of $23.5 million, or 20 cents per diluted share, on sales of $447.8 million during the three months ended March 31. That compares with profits of $24.4 million, or 21 cents per diluted share, on sales of $393.6 million during the same period last year.
PKI also announced the takeover of Seattle, Wash.-based genetic analysis and laboratory workflow software developer Geospiza Inc.
Read more
Theragenics sinks into the read on flat sales
Theragenics Corp. (NYSE:TGX) posted net earnings of $458,000, or 1 cent per diluted share, on revenue of $20.3 million during the three months ended March 31. That compares with profits of $144,000 million, or 0 cents per diluted share, on revenue of $20.3 million during the same period last year.
Read more
Smith & Nephew profits dip despite sales bump
Smith & Nephew plc (NYSE:SNN) reported profits of $231 million, or 18 cents per share, on sales of $1.06 billion during the three months ended April 2. That compares with net earnings of $240 million, or 18 cents per share, on sales of $995 million during the same period last year.
Read more
Orthofix dives into the red ink
Orthofix International N.V. (NSDQ:OFIX) reported a loss of $35.8 million, or $2.00 per diluted share, on revenue of $139.2 million during the three months ended March 31. That compares with profits of $17.5 million, or 99 cents per diluted share, on revenue of $138.8 million during the same period last year.
Read more
Wright Medical Group climbs out of the red
Wright Medical Group Inc. (NSDQ:WMGI) posted profit of $3.6 million, or 9 cents per diluted share, on sales of $135.4 million during the three months ended March 31. That compares with a loss of about $0.5 million, or 1 cent per diluted share, on sales of $131.1 million during the same period last year.
Read more
HeartWare sales race to 68 percent rise; losses double
HeartWare International Inc. (NSDQ:HTWR) posted losses of $9.4 million, or 68 cents per diluted share, on revenue of $18.0 million during the three months ended March 31. That compares a loss of $4.5 million, or 35 cents per diluted share, on revenue of $10.7 million during the same period last year.
Read more
ThermoGenesis losses ease on increased revenue
ThermoGenesis Corp. (NSDQ:KOOL) reported a loss of $845,500, or 6 cents per diluted share, on sales of $5.2 million during the three months ended March 31. That compares with a loss of $1.4 million, or 10 cents per diluted share, on sales of $4.8 million during the same period last year.
Rochester Medical losses widen despite jump in sales
Rochester Medical Corp. (NYSE:ROCM) posted a loss of $1.3 million, or 10 cents per diluted share, on sales of $12.9 million during the three months ended March 31. That compares with a loss of $351.416, or 3 cents per diluted share, on sales of $9.8 million during the same period last year.
Read more
CareFusion vaults out of the red after modest sales increase
CareFusion.Corp. (NYSE:CFN) posted profits of $45 million, or 20 cents per diluted share, on revenue of $867 million during the three months ended March 31. That compares with losses of $9 million, or 4 cents per diluted share, on revenue of $837 million during the same period last year.
Read more
IRIDEX sales, profits inch up
IRIDEX Corp. (NSDQ:IRIX) reported profits of $566,000, or 6 cents per share, on revenue of $11.2 million during the three months ended April 2. That compares with profits of $485,000, or 5 cents per share, on revenue of $10.8 million during the same period last year.
Read more
Accuray dips into the red ink
Accuray Inc. (NSDQ:ARAY) posted a loss of $1.2 million, or 2 cents per diluted share, on sales of $35.2 million during the three months ended March 31. That compares with a profit of $2.3 million, or 4 cents per diluted share, on sales of $33.8 million during the same period last year.
Read more
